Andromeda's DiaPep277 : beating a path to type 1 diabetes?
This article was originally published in Scrip
Executive Summary
Andromeda Biotech has released top-line results for its lead product, DiaPep277, that suggest it could prove an effective immunotherapeutic product for patients with newly diagnosed type 1 diabetes.